Nature Medicine retracts lung cancer timing study over integrity concerns

Nature Medicine retracted a lung cancer timing study on June 24, 2026, saying its editors no longer had confidence in the integrity of the results. The decision erased a finding that had briefly fueled hopes for a simple, low-cost way to improve cancer outcomes by changing when immunochemotherapy is given.

The paper, published online on February 2, 2026, studied 210 patients with treatment-naive stage III-IV non-small cell lung cancer in a randomized phase III trial. It reported median progression-free survival of 11.3 months for patients treated before 3 p.m. versus 5.7 months after 3 p.m., and overall survival of 28.0 months versus 16.8 months. The study was registered as NCT05549037, known as LungTIME-C01, and was sponsored by Hunan Province Tumor Hospital, also identified as Hunan Cancer Hospital, with Yongchang Zhang listed as the responsible party.

The paper drew attention because it suggested that the clock on the wall, rather than a new drug, might improve outcomes without added toxicity or cost. That made it attractive to oncologists looking for practical changes in infusion scheduling and to patients who heard that morning treatment might work better. But Nature Medicine opened a formal investigation on February 19, 2026, after concerns emerged about the study’s data and methods.

The retraction notice cited inconsistencies between the trial registration and the published protocol, along with problems involving source data, safety reporting and imaging assessments. The journal’s editors said the amount and nature of the problems left them without confidence in the results. The move followed a four-month investigation.

The episode lands hard for clinicians because the study had seemed to offer a near-frictionless intervention: no new equipment, no new medicine and no obvious new side effects. For cancer patients, the retraction means morning infusion timing should not be treated as evidence-based guidance. The broader question of whether circadian biology affects cancer therapy is still open, but it now needs independent validation before it can be translated into practice.

Researchers including Francis C. Lévi, Sumanta Pal and Chi Van Dang had already cautioned that retrospective timing findings can be confounded by frailty, travel distance, income and work schedules. The retraction shows how quickly a provocative result can move from a specialty journal into public conversation, and how much damage is done when peer review misses signals that later unravel a clinical claim.